Crizotinib (PF-02341066)

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066)是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。

规格 价格 库存 购买数量  
RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献72篇:

客户使用该产品的13个实验数据:

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066)是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。
靶点
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MUnDfZRwfG:6aXOgRZN{[Xl? NVrySGNmPDhiaB?= M3TkRmROW09? MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP NULKTIxFOjF3N{K1PFk>
BAF3 NEi1bGREgXSxdH;4bYMhSXO|YYm= MnPpOFghcA>? M1LCUGROW09? M{LMVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= MlnLNlE2PzJ3OEm=
BAF3 MYnDfZRwfG:6aXOgRZN{[Xl? NX3Ge5J{PDhiaB?= NFvSPVZFVVOR MknqR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= NX[ySGpDOjF3N{K1PFk>
Kelly NHv5eG5EgXSxdH;4bYMhSXO|YYm= MVvEUXNQ M{fFd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN M4G2SlIyPTd{NUi5
SH-SY5Y M{HkfWN6fG:2b4jpZ{BCe3OjeR?= MoPWSG1UVw>? NEPPXXBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO NICzeoQzOTV5MkW4PS=>
SMS-KCN NUfmblROS3m2b4TvfIlkKEG|c3H5 MWDEUXNQ M1X3VmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> M4\JUlIyPTd{NUi5
BAF3 Mn7FR5l1d3SxeHnjJGF{e2G7 NVjXfIpYPDhiaB?= MYjEUXNQ M2LpfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCWZXytRWxMKHerdHigTWM2OCCxZjCwMlE6KM7:TR?= NGLrTIozOTV5MkW4PS=>
3T3 NW\xcm5JTnWwY4Tpc44hSXO|YYm= M3TkVFEhcA>? M2DtU2ROW09? M3PVW2lvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? NV;ufJN4OjF6MUK0NVQ>
3T3-E NXjMbYhsTnWwY4Tpc44hSXO|YYm= NUf4WHp{OSCq NGLIdVBFVVOR NEPuOmNKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? NIXhWJAzOThzMkSxOC=>
A549 MV7LbY5ie2ViQYPzZZk> NWf2VmtDOSCq NES3fW5FVVOR MVTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGNvTVXUJItqdmG|ZTDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDIS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQCEQvF2= Mni5NlE5OTJ2MUS=
BAF3-BCL MlXtSpVv[3Srb36gRZN{[Xl? NX7Q[45POSCq MVjEUXNQ M2jxZmlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? MlfDNlE5OTJ2MUS=
HEK293 M3\2eWZ2dmO2aX;uJGF{e2G7 NWnwWmluOSCq NYLsdHVsTE2VTx?= NGP0dG1KdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP NVrEU5JyOjF6MUK0NVQ>
HEK293 MUjGeY5kfGmxbjDBd5NigQ>? MVmxJIg> MoroSG1UVw>? MVTJcohq[mm2aX;uJI9nKEmUIHHzd4V{e2WmIHHzJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjh6NzFOwG0> M2LDTFIyQDF{NEG0
Jurkat Ml3QSpVv[3Srb36gRZN{[Xl? NH;Ob4wyKGh? NFrzNFZFVVOR MXXJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO NHvJVo0zOThzMkSxOC=>
KARPAS299 NWj3RWpxU2mwYYPlJGF{e2G7 M{\jOFEhcA>? Moj6SG1UVw>? MVjJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MUeyNVgyOjRzNB?=
PAE NFP2O2hHfW6ldHnvckBCe3OjeR?= NXPUPVFmOSCq NFTodZhFVVOR MU\Jcohq[mm2aX;uJI9nKFSUS1KgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwM{m5JO69VQ>? NHfrVm8zOThzMkSxOC=>
BAF3 M4jWeGZ2dmO2aX;uJGF{e2G7 NXLxb243Oi1|IHS= MnXKSG1UVw>? M{HmPGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0> NEfvRoczOzd2MkK1Ni=>
KARPAS299 MnjRR5l1d3SxeHnjJGF{e2G7 NH7pU2ozNTNiZB?= MkDGSG1UVw>? M1;BcWlEPTB;MD6wOlQzKM7:TR?= M3HTU|I{PzR{MkWy
EBC1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjXVXI4OiCq Ml\QSG1UVw>? NWjqcmpsUUN3ME2wMlAzOyEQvF2= M4GzSVI{QTl|M{K4
HCT116 M{jHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvEO|IhcA>? MojSSG1UVw>? M1nKe2lEPTB;MUSuPFIh|ryP NXrVfXF5OjN7OUOzNlg>
MCF7 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCwcJY4OiCq MmL4SG1UVw>? NWfufHJnUUN3ME25MlU5KM7:TR?= MXqyN|k6OzN{OB?=
MDA-MB-231 NV\4TodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[2O|IhcA>? NXnhOmJkTE2VTx?= NFnzXVRKSzVyPUGwMlgh|ryP NVHPVXRPOjN7OUOzNlg>
MKN45 NVK1RmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzkNJk4OiCq MVvEUXNQ MnLpTWM2OD1yLkCxN{DPxE1? M1u5[FI{QTl|M{K4
NCI-H441 M1n5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL6O|IhcA>? MX7EUXNQ NVPG[4xGUUN3ME2xO{4zPSEQvF2= MlXSNlM6QTN|Mki=
NCI-H661 NGnsZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm3NkBp MkG4SG1UVw>? MXrJR|UxRTFzLkS3JO69VQ>? NFfnXnEzOzl7M{OyPC=>
SK-MEL-28 NWLoNnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTOO|IhcA>? NFu5SZRFVVOR MXHJR|UxRTFyLkm3JO69VQ>? NIHUSZozOzl7M{OyPC=>
SKOV3 NVq2UnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rJRlczKGh? MVvEUXNQ NHrMc5JKSzVyPUGyMlg2KM7:TR?= M4Kw[VI{QTl|M{K4
SNU5 M3jGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;pRW57PzJiaB?= MVXEUXNQ MXXJR|UxRTBwMEG2JO69VQ>? NY\xTZdZOjN7OUOzNlg>
NCI-H2228 NIS0NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp NVnPVJlbTE2VTx?= MUnJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN MUSyOFQ{OjlyOR?=
NCI-H3122 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHmzVlY4OiCq M{HNZmROW09? NUDnb29UUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? Mki5NlQ1OzJ7MEm=
NCI-H3122 M1;kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;iTFczKGh? MXfEUXNQ NFjTdWpKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> NVfER2o6OjR2M{K5NFk>
NCI-H3122 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHkW5VLPzJiaB?= MXXEUXNQ NYTDbI9RUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshVDFzOU\NJI12fGGwdDD3bZRpKEmFNUCgc4YhOC56M{ig{txO MXiyOFQ{OjlyOR?=
NIH-3T3 NUHaU21XU2mwYYPlJGF{e2G7 NEi3PYsyKGh? MWLEUXNQ M37ZXmlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP NHnVbmIzPDR|MkmwPS=>
NIH-3T3 Mki0T4lv[XOnIFHzd4F6 MoTRNUBp MUXEUXNQ NEP3eY1KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[wOUDPxE1? M2LTNVI1PDN{OUC5
NIH-3T3 NXPyVYhvU2mwYYPlJGF{e2G7 MYCxJIg> NX;oSZZnTE2VTx?= MlO3TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NXzkepE5OjR2M{K5NFk>
NIH-3T3 NIrOOZNMcW6jc3WgRZN{[Xl? NET6cZQyKGh? M1juOGROW09? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0> Mo\GNlQ1OzJ7MEm=
NIH-3T3 NXPpc2t5U2mwYYPlJGF{e2G7 MlLsNUBp MYTEUXNQ NXftUZdXUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP MWqyOFQ{OjlyOR?=
BAF3 MUnGeY5kfGmxbjDBd5NigQ>? MnHDO|IhcA>? NFvjRVhFVVOR MlTpTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> NYqzZ3FbOjR2Nki2N|I>
BAF3 MUPDfZRwfG:6aXOgRZN{[Xl? MU[3NkBp M2nwRWROW09? MXLJR|UxRTBwOUig{txO MXuyOFQ3QDZ|Mh?=
NIH-3T3 M1PDWmtqdmG|ZTDBd5NigQ>? M2T4fFEhcA>? NXPNZmc3UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BHOTF5NFygcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6xOlUh|ryP MWiyOFgyQTFzNh?=
NIH-3T3 M4XRUmtqdmG|ZTDBd5NigQ>? Moq4NUBp MXjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> MlTDNlQ5OTlzMU[=
NIH-3T3 NGT6dJFMcW6jc3WgRZN{[Xl? MnTCNUBp M2S4XGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzODKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMUS4JO69VQ>? M4HGVlI1QDF7MUG2
NIH-3T3 MX7LbY5ie2ViQYPzZZk> NUTJeIhWOSCq NGOyRVBKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= NFTud2MzPDhzOUGxOi=>
KARPAS299 MnL3T4lv[XOnIFHzd4F6 Ml;FPVAhdWmw NUDQ[4lVTE2VTx?= Mk\jTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NVLDbmZDOjR7MEC3OVA>
MKN 45 MXnLbY5ie2ViQYPzZZk> MYixJIg> MnTLSG1UVw>? MUPJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> M{[5PFI1QTByN{Ww
A549 NHu4bJhEgXSxdH;4bYMhSXO|YYm= M4X0eFQ5KGh? NEPyVHVFVVOR NU\WVHJsUUN3MDDv[kA1NjB6NDFOwG0> NVfrW4VQOjR7MEC4N|A>
NCI-H1975 NGTvOlJEgXSxdH;4bYMhSXO|YYm= M{XrVlQ5KGh? MlXzSG1UVw>? NHW0c2xKSzVyIH;mJFcvPTVzIN88US=> NXLudZc6OjR7MEC4N|A>
NCI-H1993 M3;ORmN6fG:2b4jpZ{BCe3OjeR?= NIPRVGU1QCCq M{TmUWROW09? MmHiTWM2OCCxZjCwMlA3OSEQvF2= MlvRNlQ6ODB6M{C=
NCI-H1993 M2XldGFxd3Sxc3nzJGF{e2G7 M{DSeVEh|ryP M1XESlI1KGh? MXHEUXNQ M{nQXYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NHHDSnczPDlyMEizNC=>
NIH-3T3 NVLxeGZWS3m2b4TvfIlkKEG|c3H5 MlzUOFghcA>? NXLTOG1xTE2VTx?= MWHJR|UxKG:oIECuN|Y1KM7:TR?= NIT2dnUzPDlyMEizNC=>
EBC1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnLO|IhcA>? MWfEUXNQ NGewNYNKSzVyIH;mJFAvODB4OTFOwG0> MVuyOFkxODh|MR?=
KARPAS299 NEfvfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3wO|IhcA>? MWjEUXNQ NGnyfmpKSzVyIH;mJFAvOiEQvF2= NFTGNFUzPDlyMEizNS=>
NB1 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\YbWlEPTB;OUGuPVghdk1? MWrTRW5ITVJ?
NCI-SNU-5 NGnvXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFyNT63OUBvVQ>? MUHTRW5ITVJ?
SR NHK2N5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\rd|FVUUN3ME2xNlYvOzFibl2= MkLXV2FPT0WU
SF539 M{HUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTVTWM2OD1{MESuNlQhdk1? NU[xenhwW0GQR1XS
SU-DHL-1 NYXkdIw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN|Nj64NkBvVQ>? NYj0SZVDW0GQR1XS
SCC-3 NInpVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\KZ3ljUUN3ME2zOVYvPzZibl2= NILWTnFUSU6JRWK=
DEL NVTpcmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\PWZpRUUN3ME2zOlkvQSCwTR?= NInDZnhUSU6JRWK=
CTV-1 M{PwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDH[YJKSzVyPUW5Ok41QCCwTR?= NY\u[HhlW0GQR1XS
EM-2 NX\ufWh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M336OWlEPTB;NkCxMlM1KG6P MkjGV2FPT0WU
MHH-CALL-2 NYDBcXVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17qd2lEPTB;NkiyMlU4KG6P MYjTRW5ITVJ?
KM12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\LOGlEPTB;N{C2Mlkhdk1? M2DLVnNCVkeHUh?=
KINGS-1 M{Kxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fWfmlEPTB;N{S5Mlc2KG6P M2LTUnNCVkeHUh?=
MEG-01 NG[5Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTh3Nz62OkBvVQ>? NFjGR|dUSU6JRWK=
BV-173 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwMEW5PVch|ryP MXLTRW5ITVJ?
LAMA-84 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwM{iyPFIh|ryP MXLTRW5ITVJ?
KARPAS-299 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kOGVKSzVyPUGuOFA5PjFizszN MVrTRW5ITVJ?
K-562 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwN{KyOlkh|ryP M1\R[HNCVkeHUh?=
SK-LMS-1 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPbG1ZUUN3ME2xMlc3QDZ5IN88US=> NF\PSWNUSU6JRWK=
MOLT-16 NV63PGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XCN2lEPTB;MT65OVU4PSEQvF2= MUfTRW5ITVJ?
CMK M2WwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\TVGlEPTB;MT65OlE2QSEQvF2= M3fjOnNCVkeHUh?=
ST486 NW\3RYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnEb5lKSzVyPUKuOFMxPzNizszN NV[1S3RJW0GQR1XS
CI-1 M4jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwNEm2OVkh|ryP MnHxV2FPT0WU
KP-N-RT-BM-1 NIDCNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID1XoZKSzVyPUKuO|AyOjJizszN M3LWNnNCVkeHUh?=
ALL-PO MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwMUiyNFch|ryP MlTtV2FPT0WU
KS-1 NX7aSYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHDNnVKSzVyPUOuNlEzOjVizszN M1rHbnNCVkeHUh?=
Becker M3zMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTXTWM2OD12LkKzPVMh|ryP MYrTRW5ITVJ?
GDM-1 NGjEOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3xbXdKSzVyPUSuNlQ3OTdizszN M2Pp[HNCVkeHUh?=
BC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;O[2lEPTB;ND60PVI4PyEQvF2= MWLTRW5ITVJ?
NB14 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRwOEO1NlQh|ryP MnfTV2FPT0WU
NOS-1 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKcXJSUUN3ME21MlM{QDd2IN88US=> NHLR[XlUSU6JRWK=
MZ1-PC NEDWWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwOEKxOVEh|ryP M3nTV3NCVkeHUh?=
A498 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH2OVZ6UUN3ME22MlA5PDd|IN88US=> MoHYV2FPT0WU
EW-16 NEnXSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT5bpRDUUN3ME22MlM4Pzd|IN88US=> NFLFVFJUSU6JRWK=
NALM-6 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL6cnVKSzVyPU[uOlg{QDdizszN MXTTRW5ITVJ?
EB-3 M3jkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fpRmlEPTB;Nz6wO|I{OyEQvF2= M33t[HNCVkeHUh?=
697 M1jnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzTTWM2OD17LkK0N|I6KM7:TR?= NHjrOXFUSU6JRWK=
Ramos-2G6-4C10 NUKyVGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7lXlBKSzVyPUmuOVk5PDJizszN NETub4RUSU6JRWK=
KNS-81-FD NVPXTpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTkeI1lUUN3ME25MlY6PjV|IN88US=> MX\TRW5ITVJ?
HUTU-80 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULjR4MyUUN3ME25Mlc1PjR{IN88US=> NUjaVIpXW0GQR1XS
LS-411N M33B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLiTWM2OD1zMD6wOVY4KM7:TR?= NGHt[XJUSU6JRWK=
RPMI-8402 NU\CT|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP6TWM2OD1zMD6xNVYh|ryP NULjNo55W0GQR1XS
KU812 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFyLkK5PVEh|ryP M1vHZ3NCVkeHUh?=
EW-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XCeGlEPTB;MUCuOFQzPSEQvF2= MoS5V2FPT0WU
HC-1 M2nTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorPTWM2OD1zMD60PFQ1KM7:TR?= MorUV2FPT0WU
NB69 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFyLkWwOFMh|ryP M2\yXXNCVkeHUh?=
MFH-ino NVnpbXZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;oVVVKSzVyPUGwMlg{ODNizszN MUjTRW5ITVJ?
CCRF-CEM MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LUeWlEPTB;MUGuOVk4KM7:TR?= NXy1elVoW0GQR1XS
SK-N-DZ MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILKb5pKSzVyPUGyMlA1OzZizszN MUDTRW5ITVJ?
NCI-H720 MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF{LkG3NFUh|ryP Mn7zV2FPT0WU
HCC1187 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfXdFBKSzVyPUGyMlIxPDFizszN Mm\BV2FPT0WU
IST-SL2 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrYem9[UUN3ME2xNk41QDd{IN88US=> M3L4WnNCVkeHUh?=
KE-37 NEPDRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTURoxKSzVyPUGyMlc6PjZizszN MoP6V2FPT0WU
HCC1599 NHW4VIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXFcoIxUUN3ME2xNk46ODZ7IN88US=> NWrHc|RKW0GQR1XS
A4-Fuk MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvxTWM2OD1zMj65OVg3KM7:TR?= NUX2dFN{W0GQR1XS
NKM-1 M1f1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvzdpZKSzVyPUGzMlI6OjVizszN NEDGT5BUSU6JRWK=
BE-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\QTWM2OD1zMz63PVg6KM7:TR?= MknBV2FPT0WU
MV-4-11 M4TGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\UZmlEPTB;MUSuNFMzPCEQvF2= MnzWV2FPT0WU
OPM-2 NGT0e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHTdpRKSzVyPUG0MlQxQDVizszN MUPTRW5ITVJ?
KARPAS-422 M3;YcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPITWM2OD1zND61NVI3KM7:TR?= MUHTRW5ITVJ?
RPMI-8226 M{KwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjdZlKSzVyPUG0Mlg6OTVizszN NGH3eHdUSU6JRWK=
KARPAS-45 NHrO[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXkd5BKSzVyPUG1Mlc4OTZizszN MYXTRW5ITVJ?
SK-PN-DW NIWwSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTEV2ZKSzVyPUG1Mlg3OzFizszN MUXTRW5ITVJ?
LC-2 NFG2SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX3NWpKUUN3ME2xOk4yPTB4IN88US=> MlnEV2FPT0WU
NCI-H1648 NEDMNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHzTWM2OD1zNj6yOVQh|ryP M3f4eHNCVkeHUh?=
RL95-2 NIHQ[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\yWo9kUUN3ME2xOk4{QTd6IN88US=> MULTRW5ITVJ?
KNS-42 NHHLZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjNTWM2OD1zNj63Nlc1KM7:TR?= Mlj5V2FPT0WU
RPMI-6666 M3mwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FcGlEPTB;MU[uPVIyOSEQvF2= M2TZc3NCVkeHUh?=
SIG-M5 NVKyZoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXMTGhKSzVyPUG3MlE6ODNizszN M3zweHNCVkeHUh?=
VA-ES-BJ NUL1eJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF5Lke0OVEh|ryP M1zJbXNCVkeHUh?=
MONO-MAC-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jRTmlEPTB;MUeuPVMyOiEQvF2= M4n0bXNCVkeHUh?=
LAN-6 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7lelVKSzVyPUG4Mlc2PTdizszN NUXicIFsW0GQR1XS
A388 NIm3cFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XxN2lEPTB;MUmuN|A2QSEQvF2= M17acXNCVkeHUh?=
SK-NEP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfO[|hKSzVyPUKwMlIyOzJizszN MlvkV2FPT0WU
TE-10 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJyLkWyNlEh|ryP M3jyd3NCVkeHUh?=
HL-60 NFTuclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[yTWM2OD1{MD65NFk6KM7:TR?= M{D1bnNCVkeHUh?=
MC116 NWnHUJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJzLkeyNlEh|ryP NG\lUmhUSU6JRWK=
SW962 M{HXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjlNJVIUUN3ME2yNU44QTF3IN88US=> M2HDSXNCVkeHUh?=
NOMO-1 M3vNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ{Lk[1OlQh|ryP NF7mclZUSU6JRWK=
CTB-1 M3HSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\sTWM2OD1{Mj64OlcyKM7:TR?= NX75TW5TW0GQR1XS
MRK-nu-1 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ{LkmwO|Qh|ryP Moe4V2FPT0WU
GR-ST MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\oU5BKSzVyPUKzMlc3KM7:TR?= M{\IS3NCVkeHUh?=
HH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzYVHZKSzVyPUK0MlAxOyEQvF2= NInyXY5USU6JRWK=
NCI-H1963 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvQWIlFUUN3ME2yOE4xPzh{IN88US=> MWPTRW5ITVJ?
QIMR-WIL NEjJdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jORWlEPTB;MkSuPFc4OiEQvF2= NUPYXnpRW0GQR1XS
CGTH-W-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ3LkC3NlMh|ryP NIrWXnpUSU6JRWK=
LP-1 NXfESmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ3Lk[1OVEh|ryP M{\NcXNCVkeHUh?=
NCI-H748 NEL5NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrJTWM2OD1{Nj61NVM4KM7:TR?= MXzTRW5ITVJ?
PF-382 NVnXOlUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz0ZohzUUN3ME2yO{4zOjJ|IN88US=> M1;GO3NCVkeHUh?=
ATN-1 NYXkVVRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDMTWM2OD1{Nz6zO|MzKM7:TR?= NV36[mNWW0GQR1XS
L-540 NUGwTW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nHRmlEPTB;MkeuOlQ2QSEQvF2= MmTIV2FPT0WU
LXF-289 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HITmlEPTB;MkeuO|UyQSEQvF2= M4THenNCVkeHUh?=
LS-513 M{XBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ6LkG4NFch|ryP NHjJfnlUSU6JRWK=
NCI-H1581 NWnlPWcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qy[2lEPTB;M{CuN|k4PiEQvF2= NXm0NY9TW0GQR1XS
ES6 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNyLk[4PVkh|ryP NUKyOYF4W0GQR1XS
SW982 M1Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\GTWM2OD1|MD64OVY3KM7:TR?= Moi4V2FPT0WU
DOHH-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNzLkW4PVMh|ryP MkH1V2FPT0WU
DB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPFfIlKSzVyPUOzMlk1OzFizszN MlXJV2FPT0WU
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD1|ND6xO|U3KM7:TR?= MWnTRW5ITVJ?
LB831-BLC NF7BWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPISFNKSzVyPUO0MlUyQDRizszN MXnTRW5ITVJ?
NB5 NEnvUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXuVnJmUUN3ME2zOE45PTN3IN88US=> NHq2UFVUSU6JRWK=
GB-1 NF\0UlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[xemlEPTB;M{WuNFQ3QSEQvF2= M4rYTHNCVkeHUh?=
TE-15 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDqdVdKSzVyPUO1MlIzOzhizszN M37JWHNCVkeHUh?=
LC4-1 NGK3bIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfDTWM2OD1|NT6zPFQ4KM7:TR?= MVvTRW5ITVJ?
NCI-H747 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmwTmJKSzVyPUO2MlE{PjlizszN MU\TRW5ITVJ?
NTERA-S-cl-D1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXkTWM2OD1|OD63N|Q4KM7:TR?= MkmzV2FPT0WU
SK-MM-2 NWHUcpEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO0OowyUUN3ME20NE4yOTR4IN88US=> M4jpV3NCVkeHUh?=
TGW NVzkc4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W5Z2lEPTB;NEGuNFU3OyEQvF2= M2\XfHNCVkeHUh?=
ONS-76 NIHPNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL2NFRKSzVyPUSyMlQ5QDNizszN MUnTRW5ITVJ?
CPC-N Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG3TIhKSzVyPUSyMlk6PzFizszN MmnFV2FPT0WU
ES4 NWDSdFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsWJY4UUN3ME20OE41OTV|IN88US=> NVrmVXlbW0GQR1XS
Daudi NEnsOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3pTWM2OD12NT6wPFI4KM7:TR?= NUnrTnNtW0GQR1XS
MOLT-4 M37wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17KXmlEPTB;NEWuNFg2OyEQvF2= MX;TRW5ITVJ?
HT-144 NUnrNVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O0[GlEPTB;NE[uO|I3KM7:TR?= MmTZV2FPT0WU
SW872 NF\KN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3CTWM2OD12OD6xPVM{KM7:TR?= NUS4ZXBIW0GQR1XS
D-283MED MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL3PGlNUUN3ME20PE4{PTR{IN88US=> MoPaV2FPT0WU
NCI-H2126 NWf0W24{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKyTWM2OD12OD64OFc3KM7:TR?= M4rrdnNCVkeHUh?=
NCI-SNU-16 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3VmlEPTB;NEmuNlE1OyEQvF2= MlXuV2FPT0WU
CESS NV[zWI11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi4N3BKSzVyPUS5MlUxQDhizszN MW\TRW5ITVJ?
A101D M{fCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjnb2NKSzVyPUS5Mlk4OzZizszN MlO5V2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

+ 展开
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT01970865 Active not recruiting ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC Pfizer January 8 2014 Phase 2
NCT01979536 Recruiting Anaplastic Large Cell Lymphoma ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma|CD30-Positive Neoplastic Cells Present National Cancer Institute (NCI) November 8 2013 Phase 2
NCT03297606 Recruiting Lymphoma Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer October 6 2017 Phase 2
NCT01531361 Active not recruiting Advanced Cancers M.D. Anderson Cancer Center February 6 2012 Phase 1
NCT03194893 Recruiting Neoplasms Hoffmann-La Roche July 5 2017 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID